{"id":1015987,"date":"2026-11-02T07:01:44","date_gmt":"2026-11-02T12:01:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/merck-to-present-new-data-from-its-broad-oral-hiv-portfolio-and-pipeline-at-hiv-glasgow-2026\/"},"modified":"2026-11-02T07:01:44","modified_gmt":"2026-11-02T12:01:44","slug":"merck-to-present-new-data-from-its-broad-oral-hiv-portfolio-and-pipeline-at-hiv-glasgow-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/merck-to-present-new-data-from-its-broad-oral-hiv-portfolio-and-pipeline-at-hiv-glasgow-2026\/","title":{"rendered":"Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026"},"content":{"rendered":"

<\/p>\n

Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026<\/b><\/p>\n

Presentations include data on daily and investigational once-weekly oral treatments and investigational once-monthly oral HIV pre-exposure prophylaxis<\/b><\/p>\n

New data include Phase 3 subgroup analyses and patient-reported outcomes of investigational once-weekly oral combination of islatravir\/lenacapavir (ISL\/LEN)<\/b><\/p>\n

RAHWAY, N.J.–(BUSINESS WIRE<\/a>)–
\nMerck (NYSE: MRK), known as MSD outside of the United States and Canada, announced todaythat new data across its HIV treatment and prevention pipeline and portfolio will be presented at HIV Drug Therapy Glasgow 2026 (HIV Glasgow 2026<\/a>), taking place Nov 8\u201311, 2026, in Glasgow, Scotland. Presentations will highlight Merck\u2019s strategy to expand oral options in both HIV treatment and prevention, including data on once-daily IDVYNSO\u00ae <\/sup>(doravirine\/islatravir), the investigational once-weekly oral treatment regimens islatravir\/lenacapavir (ISL\/LEN) and islatravir\/ulonivirine (ISL\/ULO), and the investigational once-monthly oral pre-exposure prophylaxis (PrEP) alimatravir (AMI, MK-8527).<\/p>\n

\n\u201cThe data being presented at HIV Glasgow reflect the breadth of our research across HIV treatment and prevention,\u201d said Dr. Luisa Stamm, associate vice president and HIV section head at Merck Research Laboratories. \u201cOur goal is to bring forward oral options, including daily and once-weekly HIV treatment regimens, as well as a once-monthly HIV prevention pill. Because no single medicine works for every person, we are committed to expanding choices that may help address the diverse needs and preferences of people living with HIV or those who could benefit from PrEP.\u201d<\/p>\n

\nAt HIV Glasgow, Merck will present Phase 3 subgroup analyses of once-daily IDVYNSO, including Week 48 resistance and weight analyses from Trial 53 comparing IDVYNSO to bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) in adults with HIV-1 who had not previously received antiretroviral treatment, as well as Week 96 patient-reported outcomes for IDVYNSO in adults with virologically suppressed HIV-1. Separately, the U.S. Food and Drug Administration (FDA) has accepted two supplemental New Drug Applications for IDVYNSO (doravirine and islatravir): one based on the Phase 3 Trial 053 in adults who had not previously received antiretroviral treatment and one based on the Phase 3 Trials 051 and 052 to include 96-week data in virologically suppressed adults. The FDA has set a Prescription Drug User Fee Act (PDUFA) or target action date of April 22, 2027, for both applications.<\/p>\n

\nIDVYNSO (doravirine\/islatravir) is a two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir and is approved in the United States for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine.<\/p>\n

\nThe investigational once-weekly oral regimen of islatravir and lenacapavir pairs Merck\u2019s islatravir, a potent nucleoside analog with multiple mechanisms of action including HIV-1 reverse transcriptase translocation inhibition, with Gilead\u2019s lenacapavir, a first-in-class capsid inhibitor that disrupts HIV-1 at multiple stages of its lifecycle. Data to be presented at HIV Glasgow from the Phase 3 ISLEND-1 and ISLEND-2 trials will include Week 48 safety and efficacy subgroup analyses across diverse demographic populations. ISLEND-2 data will also include Week 48 patient-reported outcomes and a qualitative substudy of participant and provider experiences with once-weekly dosing. These data further characterize Phase 3 safety and efficacy findings<\/a> first presented at AIDS 2026, providing additional insight across patient subgroups, treatment experiences, and preferences with once-weekly oral therapy.<\/p>\n

Key presentations at HIV Glasgow 2026 by program:<\/b><\/p>\n

Doravirine\/islatravir (once-daily oral treatment)<\/b><\/p>\n